Astrocytosis in Parkinsonism: Considering Tripartite Striatal Synapses in Physiopathology?

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2014 Oct 14

PMID 25309435

Citations 23

Authors

Giselle Charron

Evelyne Doudnikoff

Marie-Helene Canron

Qin Li

Celine Vega

Sebastien Marais

Jerome Baufreton

Anne Vital

Stephane H R Oliet

Erwan Bezard

Affiliations

Soon will be listed here.

Abstract

The current concept of basal ganglia organization and function in physiological and pathophysiological conditions excludes the most numerous cells in the brain, i.e., the astrocytes, present with a ratio of 10:1 neuron. Their role in neurodegenerative condition such as Parkinson's disease (PD) remains to be elucidated. Before embarking into physiological investigations of the yet-to-be-identified "tripartite" synapses in the basal ganglia in general and the striatum in particular, we therefore characterized anatomically the PD-related modifications in astrocytic morphology, the changes in astrocytic network connections and the consequences on the spatial relationship between astrocytic processes and asymmetric synapses in normal and PD-like conditions in experimental and human PD. Our results unravel a dramatic regulation of striatal astrocytosis supporting the hypothesis of a key role in (dys) regulating corticostriatal transmission. Astrocytes and their various properties might thus represent a therapeutic target in PD.

Citing Articles

Neuroprotective Effect of Maresin-1 in Rotenone-Induced Parkinson's Disease in Rats: The Putative Role of the JAK/STAT Pathway.

Khodir S, Sweed E, Faried M, Abo Elkhair D, Khalil M, Afifi K Neurochem Res. 2024; 50(1):30.

PMID: 39576344 PMC: 11584474. DOI: 10.1007/s11064-024-04282-x.

Connexin 30 Deficiency Ameliorates Disease Progression at the Early Phase in a Mouse Model of Amyotrophic Lateral Sclerosis by Suppressing Glial Inflammation.

Hashimoto Y, Yamasaki R, Ko S, Matsuo E, Kobayakawa Y, Masaki K Int J Mol Sci. 2022; 23(24).

PMID: 36555685 PMC: 9782489. DOI: 10.3390/ijms232416046.

Therapeutic Potential of Astrocyte Transplantation.

Hastings N, Kuan W, Osborne A, Kotter M Cell Transplant. 2022; 31:9636897221105499.

PMID: 35770772 PMC: 9251977. DOI: 10.1177/09636897221105499.

[Inhibition connexin 43 by mimetic peptide Gap27 mediates protective effects on 6-hydroxydopamine induced Parkinson's disease mouse model].

Quan H, Xu W, Qi Y, Li Q, Zhou H, Huang J Beijing Da Xue Xue Bao Yi Xue Ban. 2022; 54(3):421-426.

PMID: 35701117 PMC: 9197703.

Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson's disease.

Paul Choudhury S, Bano S, Sen S, Suchal K, Kumar S, Nikolajeff F NPJ Parkinsons Dis. 2022; 8(1):66.

PMID: 35650269 PMC: 9160246. DOI: 10.1038/s41531-022-00324-9.

References

Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E . Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis. 2007; 26(2):452-63. DOI: 10.1016/j.nbd.2007.02.001. View

Suarez L, Solis O, Carames J, Taravini I, Solis J, Murer M . L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol Psychiatry. 2013; 75(9):711-22. DOI: 10.1016/j.biopsych.2013.05.006. View

Scholz B, Svensson M, Alm H, Skold K, Falth M, Kultima K . Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. PLoS One. 2008; 3(2):e1589. PMC: 2217596. DOI: 10.1371/journal.pone.0001589. View

Gomide V, Chadi G . Glial bFGF and S100 immunoreactivities increase in ascending dopamine pathways following striatal 6-OHDA-induced partial lesion of the nigrostriatal system: a sterological analysis. Int J Neurosci. 2005; 115(4):537-55. DOI: 10.1080/00207450590521064. View

Sorci G, Bianchi R, Riuzzi F, Tubaro C, Arcuri C, Giambanco I . S100B Protein, A Damage-Associated Molecular Pattern Protein in the Brain and Heart, and Beyond. Cardiovasc Psychiatry Neurol. 2010; 2010. PMC: 2933911. DOI: 10.1155/2010/656481. View

Calabresi P, Centonze D, Gubellini P, Marfia G, Pisani A, Sancesario G . Synaptic transmission in the striatum: from plasticity to neurodegeneration. Prog Neurobiol. 2000; 61(3):231-65. DOI: 10.1016/s0301-0082(99)00030-1. View

Santello M, Cali C, Bezzi P . Gliotransmission and the tripartite synapse. Adv Exp Med Biol. 2012; 970:307-31. DOI: 10.1007/978-3-7091-0932-8_14. View

Dermietzel R, Hertberg E, Kessler J, Spray D . Gap junctions between cultured astrocytes: immunocytochemical, molecular, and electrophysiological analysis. J Neurosci. 1991; 11(5):1421-32. PMC: 6575331. View

Fasano S, Bezard E, DAntoni A, Francardo V, Indrigo M, Qin L . Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A. 2010; 107(50):21824-9. PMC: 3003069. DOI: 10.1073/pnas.1012071107. View

10.

Hirsch E, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel P . The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci. 2003; 991:214-28. DOI: 10.1111/j.1749-6632.2003.tb07478.x. View

11.

Sathe K, Maetzler W, Lang J, Mounsey R, Fleckenstein C, Martin H . S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. Brain. 2012; 135(Pt 11):3336-47. PMC: 3501971. DOI: 10.1093/brain/aws250. View

12.

Tsacopoulos M, Magistretti P . Metabolic coupling between glia and neurons. J Neurosci. 1996; 16(3):877-85. PMC: 6578818. View

13.

Gerfen C, Surmeier D . Modulation of striatal projection systems by dopamine. Annu Rev Neurosci. 2011; 34:441-66. PMC: 3487690. DOI: 10.1146/annurev-neuro-061010-113641. View

14.

Santini E, Sgambato-Faure V, Li Q, Savasta M, Dovero S, Fisone G . Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS One. 2010; 5(8):e12322. PMC: 2925943. DOI: 10.1371/journal.pone.0012322. View

15.

Dumartin B, Caille I, Gonon F, Bloch B . Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists. J Neurosci. 1998; 18(5):1650-61. PMC: 6792610. View

16.

Chaudhry F, Lehre K, van Lookeren Campagne M, Ottersen O, Danbolt N, Storm-Mathisen J . Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry. Neuron. 1995; 15(3):711-20. DOI: 10.1016/0896-6273(95)90158-2. View

17.

Rothstein J, Pardo C, Bristol L, Jin L, Kuncl R, Kanai Y . Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996; 16(3):675-86. DOI: 10.1016/s0896-6273(00)80086-0. View

18.

Henning J, Strauss U, Wree A, Gimsa J, Rolfs A, Benecke R . Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease. Neurosci Res. 2008; 62(4):246-53. DOI: 10.1016/j.neures.2008.09.001. View

19.

Raju D, Ahern T, Shah D, Wright T, Standaert D, Hall R . Differential synaptic plasticity of the corticostriatal and thalamostriatal systems in an MPTP-treated monkey model of parkinsonism. Eur J Neurosci. 2008; 27(7):1647-58. DOI: 10.1111/j.1460-9568.2008.06136.x. View

20.

Goubard V, Fino E, Venance L . Contribution of astrocytic glutamate and GABA uptake to corticostriatal information processing. J Physiol. 2011; 589(Pt 9):2301-19. PMC: 3098705. DOI: 10.1113/jphysiol.2010.203125. View